Anthropic Revenue Surge Signals Strong AI Market Momentum in 2026 
X Corp Loses Legal Battle Over Australia Child Safety Fine 
Samsung Shares Surge After Strike Deal Eases Labor Tensions 
Goldman Sachs to Pay $500M in 1MDB Shareholder Fraud Settlement 
Walmart Stock Falls Despite Strong Q1 Revenue Beat and E-Commerce Growth 
Boeing Wins Fraud Lawsuit Over 737 MAX Filed by LOT Polish Airlines 
GameStop Raises eBay Stake to 6.6% as Ryan Cohen Pushes $56 Billion Takeover Bid 
Macquarie Names Five Taiwan AI Stocks Set to Benefit From Data Center Growth in 2026 
Huawei Chip Breakthrough Sparks Rally in Chinese Semiconductor Stocks 
PDG Explores $1 Billion Sale of China Data Center Assets 
NHS shakeup: if it sounds like we’ve been here before, it’s because we have 
SoftBank Shares Surge as OpenAI IPO Buzz and SB Energy Filing Boost AI Optimism 
Texas Sues Meta Over WhatsApp Encryption Claims 
Lam Research Expands AI-Powered Semiconductor Tools and Arizona Operations 
OpenAI Eyes IPO Filing as Early as This Week Amid Rising AI Competition 
SpaceX Starship V3 Test Flight Boosts IPO Momentum Ahead of Historic Market Debut 
OpenAI Expands Globally with First Overseas AI Lab in Singapore 
 and Lead Plaintiff Deadline - March 13, 2017 - EconoTimes)
NEW YORK, Feb. 02, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo" or the "Company") (NYSE:NVO) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased Novo American Depositary Receipts ("ADR") between April 30, 2015 and October 27, 2016, both dates inclusive (the “Class Period”). Investors with losses in excess of $1 million are advised to join this case by visiting the firm’s site: http://www.bgandg.com/nvo.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period, Novo reported materially false and misleading Company earnings and predications in that they were inflated through the collusive price fixing of Novo’s insulin drugs. The Complaint also alleges that Novo misrepresented and concealed the true extent of the pricing pressures it was experiencing from pharmacy benefit managers.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/nvo or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. Investors with losses in excess of $1 million in Novo have until March 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
